Bank of America Corp DE Has $8.93 Million Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Bank of America Corp DE decreased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 699,026 shares of the biopharmaceutical company's stock after selling 124,301 shares during the period. Bank of America Corp DE owned approximately 0.53% of Dynavax Technologies worth $8,927,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 2,034 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies during the fourth quarter valued at about $71,000. Nisa Investment Advisors LLC boosted its stake in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Finally, KBC Group NV grew its holdings in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 2,857 shares during the period. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Trading Up 2.7%

DVAX traded up $0.26 during trading on Thursday, reaching $9.76. The company had a trading volume of 2,053,593 shares, compared to its average volume of 2,213,229. The firm's 50-day simple moving average is $11.16 and its 200 day simple moving average is $12.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 54.22 and a beta of 1.26. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. JMP Securities cut their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. Wall Street Zen cut Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $24.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.